SQLite Web: event

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-164025.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-164025.txt","company":"Verrica Pharmaceuticals Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-164025.txt","article_chars":3291,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_49e12bbb585bbbde","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-164025.txt","content_type":"text/plain","enriched_at":"2026-04-21T05:55:10.343796+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-164025.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-164025.txt","source_event_id":"evt_cd1264878f3a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"9d6fd8bd1f4d85d8","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-20","2026-04-21","June 4, 2026","June 5, 2026","May 22, 2026","December 31, 2026"],"entities":[{"asset_class":"equity","name":"Verrica Pharmaceuticals Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"other","name":"KPMG LLP","relevance":"medium","symbol":"","type":"auditor"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; only that a DEFA14A was filed is evidenced.","The text does not specify whether DEFA14A was filed by the registrant or another party (the header includes both options but does not explicitly confirm which box is checked in the provided excerpt).","No financial guidance or financial implications are disclosed in the provided text beyond governance items (director election, advisory compensation vote, auditor ratification, equity incentive plan).","No details are provided about the proxy solicitation context beyond the voting notice/overview."],"key_facts":["Form type: DEFA14A (Schedule 14A proxy statement materials).","The notice states the annual meeting will be held on June 5, 2026 at 10:00 AM EDT.","The notice states stockholders can vote by June 4, 2026 at 11:59 PM ET.","The notice indicates stockholders can access the notice/proxy statement and Form 10-K online or request free paper/email copies prior to May 22, 2026.","Board voting items listed: (1) Election of Directors (nominees: Paul B. Manning; Lawrence Eichenfield).","Board voting items listed: (2) Advisory approval of named executive officers\u2019 compensation.","Board voting items listed: (3) Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.","Board voting items listed: (4) Approval of the Company\u2019s Amended and Restated 2018 Equity Incentive Plan.","The filing includes voting instructions via ProxyVote.com and provides a control number reference (control numbers shown in text: V90640-P50047 and V90641-P50047)."],"numeric_claims":[{"label":"Annual meeting date","value":"June 5, 2026"},{"label":"Annual meeting time (EDT)","value":"10:00 AM"},{"label":"Vote deadline (ET)","value":"June 4, 2026 11:59 PM ET"},{"label":"Copy request deadline","value":"May 22, 2026"},{"label":"Fiscal year end for auditor ratification","value":"December 31, 2026"},{"label":"ProxyVote control reference","value":"V90640-P50047 / V90641-P50047"}],"primary_claim":"Verrica Pharmaceuticals Inc. filed Form DEFA14A (Schedule 14A proxy statement materials) on 2026-04-20/2026-04-21, covering the 2026 annual meeting proposals and voting instructions.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Verrica Pharmaceuticals Inc. filed a Schedule 14A proxy-related filing on Form DEFA14A. The filing provides notice/overview of proposals for the company\u2019s 2026 annual meeting and voting logistics.","topics":["SEC filing","proxy statement","annual meeting","corporate governance","equity incentive plan","auditor ratification","director election","executive compensation (advisory)"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Verrica Pharmaceuticals Inc. \u00b7 Filed 20260420","ticker":"VRCA","tickers":["VRCA"],"title":"VRCA filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1660334/0001193125-26-164025.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — signals

Update row sig_c8bfd87f8aee in signals